TORONTO & MONTREAL & VANCOUVER, British Columbia December 19, 2016 -Versant Ventures today announced that Toronto-based portfolio company Northern Biologics Inc. has executed a transformational deal that expands its pipeline and financial resources, bringing commitments to Versant’s Canadian biotech portfolio to over CAD$500 million.

Proteocyte Diagnostics Inc. announced new support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) for their novel prognostic oral cancer laboratory service.

Vancouver and Toronto, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI).

TORONTO and NEW YORK (November 3, 2016) — Synaptive Medical, a leading medical device and technology company that pursues connections to transform the process of care, announced today that General Atlantic, a global growth equity firm, has made a strategic investment in the company. With over 35 years of experience investing in 250 growth companies and deep expertise in the healthcare and technology sectors, General Atlantic partners with entrepreneurs and management teams around the world to help them accelerate growth and become market leaders.

IT’S A START is an exciting and interactive pitch competition taking place at Digifest 2017. Pitch your business, convince expert judges of its value, and wow the crowd in 5 minutes, and you will have the chance to meet with investors, win thousands in cash, incubation space, and mentorship.

ventureLAB has started a monthly podcast featuring a topic relevant to entrepreneurs, intrapreneurs and the companies that want to work with them. From crowdfunding for equity to agile business planning, you'll hear from experts and entrepreneurs, and get the grass roots knowledge on what the ventureLAB innovation ecosystem is all about!

The GAPP promotes the commercialization and translation of genomics-derived technologies. It provides a unique opportunity for User organizations to leverage their R&D investments with public funding. GAPP fosters academic collaborations with Users from industry, government, not-for-profits, and other organizations. Successful projects are driven by the User and focus on areas of opportunity that they have identified.

Ontario Genomics is pleased to introduce this report on synthetic biology in Ontario.
Biology holds the key to all of humanity’s industrial, environmental and health challenges. What is left for us to do is pinpoint the right solutions from the genomes of millions of living organisms and put them to use in our factories, our hospitals and our homes.

Are you a Canadian IT, life sciences, robotics or foodtech company ready to grow and commercialize in the US market?

The Canadian Technology Accelerator in Boston is an award-winning 4-month immersion program that connects Canadian companies to US clients, strategic partners, and investors! Managed and operated by the Consulate General of Canada in Boston's Trade Commissioner Service team in close partnership with the CENE.

The Canadian Technology Accelerator (CTA) program of Global Affairs Canada provides Canadian high-growth companies with mentoring support, networking opportunities and temporary office space for greater exposure to global partners and markets. 

October 3, 2016 – Montreal, QC, Toronto and Ottawa, ON ─ KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co-developing since 2015.

The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom-engineered therapeutic developed at NRC.

September 20, 2016, New York — Synaptive Medical, a medical device company relentlessly pursuing connections to transform the process of care, has successfully installed their BrightMatter™ technology at Mount Sinai Health System in New York City. Mount Sinai, ranked #12 in the country by U.S. News & World Report for its neurology and neurosurgery program, is the first hospital in the New York Metropolitan area to acquire this revolutionary technology.

For the full press release, click here